PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2114669
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2114669
According to Mordor Intelligence, the home healthcare market size was valued at USD 335.22 billion in 2025 and is estimated to grow from USD 363.58 billion in 2026 to reach USD 545.69 billion by 2031, at a CAGR of 8.46% during the forecast period (2026-2031).

This report is Segmented by Healthcare Type (Equipment [Therapeutic Equipment {Insulin Delivery Devices, and More}, Diagnostic & Monitoring Equipment, and More], Services [Skilled Nursing, and More], and Software [Agency Administration, and More]), Indication (Cardiovascular, Diabetes and More) and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).
The World Health Organization estimates that 1.4 billion people will be aged 60 plus by 2030, with 80% residing in low- and middle-income nations where institutional long-term care remains limited. Each added year of life expectancy beyond 75 correlates with three to five additional years of chronic-disease management that is less costly when delivered at home than in skilled-nursing facilities. Japan already spends heavily on community-based integrated care under its long-term care insurance scheme, providing a template for other super-aged societies. In China, the 14th Five-Year Plan mandates a 15-minute radius for elderly community services in urban areas, driving local demand for portable diagnostics and telemedicine that link township clinics to tertiary centers. As similar demographic pivots unfold across Europe and North America, the home healthcare market benefits directly from scaled, policy-backed patient migration out of acute settings.
The Centers for Medicare & Medicaid Services permanently added CPT codes 99453, 99454, 99457, and 99458, reimbursing providers for device setup, data transmission, and monthly physiologic review, thus normalizing remote-patient monitoring across urban and rural settings alike. Commercial insurers such as UnitedHealthcare and Humana now pay 85-90% of in-office rates for similar services, closing the margin gap that once hindered physician adoption. The shift converts hardware into a recurring revenue model whereby manufacturers subsidize devices and earn subscription fees, mirroring consumer-wearable economics yet underpinned by clinical-grade accuracy and FDA oversight.
The United States faces a projected 78,000-nurse deficit by 2026, and home-health-aide turnover tops 65% in several states, limiting agencies' capacity to accept new patients even as demand rises. Median aide pay of USD 13.50 per hour lags other service sectors, forcing agencies to raise wages 12-18% since 2024, compressing margins that averaged 3-5% pre-pandemic.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Equipment represented 48.56% of the home healthcare market in 2025, spotlighting the capital intensity of therapeutic gear such as ventilators, dialysis systems, and insulin pumps. Therapeutic equipment revenues gain from Medicare's policy that reimburses home dialysis at 80-90% of in-center rates, enlarging the home healthcare market size for renal-care technology by routing high-acuity procedures into domestic environments. Diagnostic and monitoring devices become more affordable; fingerstick glucometer average selling prices fell 25% between 2023 and 2025 as continuous glucose monitors captured share, compressing margins for legacy products. Mobility assist equipment faces direct-to-consumer pressure that widens geographic reach but thins distributor profits.
Services constitute the second-largest 2025 slice, yet staffing deficits force agencies to triage high-acuity cases while technology offsets some labor gaps through remote vitals monitoring and tele-therapy. Hospice and palliative care expand steadily as Medicare's hospice benefit lowers financial barriers, and tele-homecare volumes stay elevated under permanent billing codes. Software platforms, though starting from a smaller base, are forecast to post a 12.25% CAGR through 2031 as electronic visit verification and open FHIR APIs become prerequisites for payer contracts. The FDA's Software as a Medical Device framework adds regulatory hurdles yet confers clinical credibility that hastens commercial adoption.
North America commanded 42.13% of 2025 revenue, powered by 52% Medicare Advantage penetration and CMS waivers that reimburse inpatient-level services rendered at home. Yet clinician shortages constrain capacity: certified-aide turnover exceeds 65%, and agencies often cap referrals, slowing potential expansion despite payer demand. Canada's funding for home care remains under 4% of total health expenditure, and Mexico's telemedicine pilots are creating incremental device demand as coverage extends into rural states.
Asia-Pacific is forecast to lead growth at 9.51% CAGR through 2031, propelled by Japan's super-aged demographic profile and Kaigo Hoken reforms that fund comprehensive in-home services. China mandates proximal community care, while India's Production Linked Incentive scheme subsidizes local device manufacturing, slicing retail prices for basic monitors by up to 30%. South Korea and Australia experiment with outcome-tied payment models that reward agencies for avoiding readmissions rather than maximizing visit counts.
Europe sustains meaningful share, with the United Kingdom's virtual wards and Germany's fast-track reimbursements for digital therapeutics broadening access. France's hospitalisation a domicile handled 120,000 patients in 2024, predominantly for intravenous antibiotics and chemotherapy, underscoring the region's advanced policy backing. Italy and Spain offer limited public reimbursement, producing a two-tier landscape in which affluent households fund private care while others rely on informal caregivers.
Smaller yet accelerating markets include the Gulf Cooperation Council states, which invest sovereign capital into smart-home monitoring, and South Africa, where private insurers pilot remote monitoring for HIV adherence. Brazil's Programa Melhor em Casa treated 200,000 patients in 2024 but remains unevenly distributed, indicating latent demand for devices and software in underserved northern regions.